Hepatitis B Virus (HBV)

Atorvastatin calcium: EFFICACY(7)

In the comparative study of atorvastatin versus niacin in patients with combined hyperlipidemia, atorvastatin 10 mg/ day was more effective in reducing levels of components of lDL-C, while niacin (3 g/day) was more effective in lowering :he components of VLDL-C . Atorvastatin had a more fa-ourable safety profile than niacin. Compliance rates, withdrawals due to adverse events and treatment-associated idverse events were all lower in the atorvastatin-treated pa-ients than in niacin-treated patients.

Patients with isolated hypertriglyceridemia

Treatment with atorvastatin positively changed the lipid pro-ile of patients with isolated hypertriglyceridemia (Fredrick-on type IV), reducing both the cholesterol and triglyceride-‘ich fractions. In a placebo controlled, double-blind, dose-esponse study that comprised patients with hypertriglyc-ridemia, atorvastatin reduced triglyceride levels in a dose-dependent manner from 26% to 46% and VLDL-C levels from 34% to 58%, respectively, at doses from 5 to 80 mg/day.

In two separate randomized, comparative studies that omprised patients with hypertriglyceridemia, atorvastatin was compared with niacin and fenofibrate . In contrast 😮 niacin and fenofibrate, both of which produced an increase n LDL-C level, atorvastatin decreased LDL-C and total cho-esterol levels. Niacin and fenofibrate were more effective han atorvastatin in reducing triglyceride and VLDL-C levels. The three treatments were comparable in reducing the non-HDL-C to HDL-C ratio. In this patient population, atorvasta-in was better tolerated than niacin and fenofibrate. Overall, hese studies suggest that atorvastatin is also an effective ipid-lowering therapy for patients with hypertriglyceridemia. buy ortho tri-cyclen online

Category: Calcium

Tags: Atorvastatin, Coronary artery disease, Dyslipidemia, HMG-CoA reductase inhibitors, Hypercholesterolemia, Statins

Leave a Reply

Your email address will not be published. Required fields are marked *